Friday, March 31, 2023
Clinical Advances in
Obesity is a serious global epidemic and increasing threat to healthcare systems, with huge financial implications. At least 1.1 billion adults are overweight, including 312 million who are obese. Compared with patients of normal weight, risk of death increases by 20%-40% in overweight individuals and by two-to threefold in obese individuals. The Clinical Advances in Treating Obesity as a Chronic Disease: Novel Insights and Strategies curriculum provides education on the latest clinical trial results and therapeutic strategies for obesity management.
Supported by an independent educational grant from
Novo Nordisk A/S
Developed through a partnership between Medscape, World Obesity Federation, and World Organization of Family Doctors.
See All
Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations
Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update
See All
Steering Committee Chair
Professor of Medicine, Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Antwerp, Belgium
Professor of Medicine, Northwestern University Feinberg School of Medicine; Director, Center for Lifestyle Medicine, Northwestern Medicine, Chicago, Illinois, United States
Faculty of Medicine, Department of Medicine, Imperial College London, London, United Kingdom
Associate Professor of Medicine, Division of Endocrinology Metabolism and Diabetes; University of Colorado Anschutz Medical Campus; Associate Professor of Epidemiology, Colorado School of Public Health, Aurora, USA
Head of the Obesity & Metabolic Syndrome Unit, Department of Endocrinology & Metabolism, University of São Paulo Medical School, São Paulo, Brazil
Professor of Medicine
University of Liverpool
Liverpool, United Kingdom
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck Sharp & Dohme Corp..; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck Sharp & Dohme Corp..; Novo Nordisk; Sanofi
Received grants for clinical research from: EU (Hepadip + Resolve consortium); Intarcia Therapeutics, Inc.; SERVIER
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Novo Nordisk, Retrofit, Weight Watchers
Received grants for clinical research from: Aspire Bariatrics; Eisai
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: GI Dynamics; Herbalife; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Herbalife; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck Sharp & Dohme Corp.; Novo Nordisk
Received grants for clinical research from: Science Foundation Ireland, Health Research Board Ireland
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk; Pfizer Inc.; Rhythm; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca; Janssen Pharmaceuticals; Merck & Co., Inc.; Novo Nordisk; Orexigen Therapeutics, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Lilly; Novo Nordisk
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Mundipharma; Merck & Co., Inc.; Napp; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Napp; Novo Nordiskl Mundipharma; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Novo Nordisk